title: A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
authors.forename: Hélène
authors.initials: H
authors.lastname: Blasco
authors.forename: Michéle
authors.initials: M
authors.lastname: Boisdron-Celle
authors.forename: Philippe
authors.initials: P
authors.lastname: Bougnoux
authors.forename: Gilles
authors.initials: G
authors.lastname: Calais
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Tournamille
authors.forename: Joseph
authors.initials: J
authors.lastname: Ciccolini
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Autret-Leca
authors.forename: Chantal
authors.initials: C
authors.lastname: Le Guellec
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000235:genetics*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil